Article Text

Download PDFPDF

Correspondence response
Response to: ‘Belimumab and the measurement of fatigue’ by Mazzoni
  1. V Strand1,
  2. R A Levy2,
  3. R Cervera3,
  4. M Petri4
  1. 1Division Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA
  2. 2Department of Medicine, Universidade do Estado do Rio de Janeiro, Brazil
  3. 3Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain
  4. 4Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
  1. Correspondence to Dr Vibeke Strand, Division Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California 94028, USA; vstrand{at}

Statistics from

We agree that fatigue is a common and important symptom of patients with active systemic lupus erythematosus (SLE), and that it is multidimensional, as has been elegantly described in patients with rheumatoid arthritis.1 In fact, randomised controlled trials in SLE have assessed fatigue, as early as the prasterone dehydroepiandrosterone (DHEA) studies (published in 2002–2004) that employed the (Krupp) Fatigue Severity Scale (FSS), developed …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles